The N-terminus of the intrinsically disordered protein α-synuclein triggers membrane binding and helix folding.

[1]  T. Schleich,et al.  Circular dichroism and gel filtration behavior of subtilisin enzymes in concentrated solutions of guanidine hydrochloride. , 1975, Biochemistry.

[2]  S. Provencher,et al.  Estimation of globular protein secondary structure from circular dichroism. , 1981, Biochemistry.

[3]  R. Epand,et al.  Human apolipoprotein A-I forms thermally stable complexes with anionic but not with zwitterionic phospholipids. , 1986, The Journal of biological chemistry.

[4]  R. L. Baldwin,et al.  Parameters of helix–coil transition theory for alanine‐based peptides of varying chain lengths in water , 1991, Biopolymers.

[5]  G. Anantharamaiah,et al.  The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. , 1992, Journal of lipid research.

[6]  P. Lansbury,et al.  The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease? , 1995, Chemistry & biology.

[7]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[8]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[9]  Hitoshi Takahashi,et al.  α-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy , 1998, Neuroscience Letters.

[10]  A. Jonas,et al.  Stabilization of α-Synuclein Secondary Structure upon Binding to Synthetic Membranes* , 1998, The Journal of Biological Chemistry.

[11]  Olaf Riess,et al.  AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.

[12]  R. Krüger,et al.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.

[13]  P. Blumbergs,et al.  Multiple-system atrophy: a new alpha-synuclein disease? , 1998, Lancet.

[14]  P. Blumbergs,et al.  In Situ and in Vitro Study of Colocalization and Segregation of α-Synuclein, Ubiquitin, and Lipids in Lewy Bodies , 2000, Experimental Neurology.

[15]  P. Lansbury,et al.  Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[16]  D. Eliezer,et al.  Conformational properties of alpha-synuclein in its free and lipid-associated states. , 2001, Journal of molecular biology.

[17]  Michel Goedert,et al.  Alpha-synuclein and neurodegenerative diseases , 2001, Nature Reviews Neuroscience.

[18]  M. Zhong,et al.  Determination of protein-drug binding constants by pressure-assisted capillary electrophoresis (PACE)/frontal analysis (FA). , 2002, Journal of pharmaceutical and biomedical analysis.

[19]  V. Uversky,et al.  Amino acid determinants of alpha-synuclein aggregation: putting together pieces of the puzzle. , 2002, FEBS letters.

[20]  Ralf Langen,et al.  Structural Organization of α-Synuclein Fibrils Studied by Site-directed Spin Labeling* , 2003, Journal of Biological Chemistry.

[21]  Reinhard Jahn,et al.  A Broken α-Helix in Folded α-Synuclein* , 2003, The Journal of Biological Chemistry.

[22]  D. Eliezer,et al.  A structural and functional role for 11-mer repeats in alpha-synuclein and other exchangeable lipid binding proteins. , 2003, Journal of molecular biology.

[23]  V. Buchman,et al.  Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease , 2003, Neuropharmacology.

[24]  J. Hoenicka,et al.  The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.

[25]  C. Haass,et al.  α-Synuclein Has a High Affinity for Packing Defects in a Bilayer Membrane , 2004, Journal of Biological Chemistry.

[26]  Andrew B West,et al.  Molecular pathophysiology of Parkinson's disease. , 2005, Annual review of neuroscience.

[27]  Luca Pinato,et al.  A Topological Model of the Interaction between α-Synuclein and Sodium Dodecyl Sulfate Micelles† , 2005 .

[28]  Karen A. Lewis,et al.  A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. , 2005, The Journal of biological chemistry.

[29]  A. Bax,et al.  Comparison of Structure and Dynamics of Micelle-bound Human α-Synuclein and Parkinson Disease Variants* , 2005, Journal of Biological Chemistry.

[30]  Luca Pinato,et al.  A topological model of the interaction between alpha-synuclein and sodium dodecyl sulfate micelles. , 2005, Biochemistry.

[31]  C. Griesinger,et al.  Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Ad Bax,et al.  Structure and Dynamics of Micelle-bound Human α-Synuclein* , 2005, Journal of Biological Chemistry.

[33]  C. Dobson,et al.  Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations. , 2005, Journal of the American Chemical Society.

[34]  Philip J. Thomas,et al.  A Precipitating Role for Truncated α-Synuclein and the Proteasome in α-Synuclein Aggregation , 2005, Journal of Biological Chemistry.

[35]  Ralf Langen,et al.  Mechanism of endophilin N‐BAR domain‐mediated membrane curvature , 2006, The EMBO journal.

[36]  Thomas Huber,et al.  Curvature and hydrophobic forces drive oligomerization and modulate activity of rhodopsin in membranes. , 2006, Biophysical journal.

[37]  S. Lindquist,et al.  α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's Models , 2006, Science.

[38]  F. Kamp,et al.  Binding of α-Synuclein Affects the Lipid Packing in Bilayers of Small Vesicles* , 2006, Journal of Biological Chemistry.

[39]  Helmut Grubmüller,et al.  Molecular Anatomy of a Trafficking Organelle , 2006, Cell.

[40]  G M Anantharamaiah,et al.  Correction for Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation , 2010 .

[41]  H. Kato,et al.  Calcium-triggered membrane interaction of the alpha-synuclein acidic tail. , 2006, Biochemistry.

[42]  A. Fink.  The Aggregation and Fibrillation of α‐Synuclein , 2006 .

[43]  K. Beyer.  Mechanistic aspects of Parkinson's disease: alpha-synuclein and the biomembrane. , 2007, Cell biochemistry and biophysics.

[44]  D. Selkoe,et al.  Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.

[45]  Michael F. Brown,et al.  Raftlike mixtures of sphingomyelin and cholesterol investigated by solid-state 2H NMR spectroscopy. , 2008, Journal of the American Chemical Society.

[46]  Jack H. Freed,et al.  Membrane-bound alpha-synuclein forms an extended helix: long-distance pulsed ESR measurements using vesicles, bicelles, and rodlike micelles. , 2008, Journal of the American Chemical Society.

[47]  A. Herrmann,et al.  Characterization of the ternary mixture of sphingomyelin, POPC, and cholesterol: support for an inhomogeneous lipid distribution at high temperatures. , 2008, Biophysical journal.

[48]  Ralf Langen,et al.  Structure of membrane-bound α-synuclein from site-directed spin labeling and computational refinement , 2008, Proceedings of the National Academy of Sciences.

[49]  Martina Huber,et al.  Antiparallel arrangement of the helices of vesicle-bound alpha-synuclein. , 2008, Journal of the American Chemical Society.

[50]  L. Bubacco,et al.  Broken helix in vesicle and micelle-bound alpha-synuclein: insights from site-directed spin labeling-EPR experiments and MD simulations. , 2008, Journal of the American Chemical Society.

[51]  V. Subramaniam,et al.  Lipid bilayer disruption by oligomeric alpha-synuclein depends on bilayer charge and accessibility of the hydrophobic core. , 2009, Biochimica et biophysica acta.

[52]  Jason D. Perlmutter,et al.  Curvature dynamics of alpha-synuclein familial Parkinson disease mutants: molecular simulations of the micelle- and bilayer-bound forms. , 2009, The Journal of biological chemistry.

[53]  T. Takenawa,et al.  Mechanisms of membrane deformation by lipid-binding domains. , 2009, Progress in lipid research.

[54]  P. Lansbury,et al.  The first N-terminal amino acids of alpha-synuclein are essential for alpha-helical structure formation in vitro and membrane binding in yeast. , 2009, Journal of molecular biology.

[55]  Ad Bax,et al.  Multiple tight phospholipid-binding modes of alpha-synuclein revealed by solution NMR spectroscopy. , 2009, Journal of molecular biology.

[56]  D. Eliezer,et al.  Charge neutralization and collapse of the C‐terminal tail of alpha‐synuclein at low pH , 2009, Protein science : a publication of the Protein Society.

[57]  E. Lemke,et al.  Interplay of α-synuclein binding and conformational switching probed by single-molecule fluorescence , 2009, Proceedings of the National Academy of Sciences.

[58]  R. Nicoll,et al.  Increased Expression of α-Synuclein Reduces Neurotransmitter Release by Inhibiting Synaptic Vesicle Reclustering after Endocytosis , 2010, Neuron.

[59]  C. Dobson,et al.  Differential Phospholipid Binding of α-Synuclein Variants Implicated in Parkinson’s Disease Revealed by Solution NMR Spectroscopy† , 2009, Biochemistry.